<DOC>
	<DOCNO>NCT03082339</DOCNO>
	<brief_summary>Scientific clinical data report shorten QTc-interval patient treat cortisone . Peal et al . analyzed chemical suppression long QT syndrome ( Type 2 ) vivo zebrafish model . Their study reveal flurandrenolide reproducibly suppress long QT phenotype via glucocorticoid signal pathway . In contrast treatment dexamethasone testosterone , treatment pure mineralocorticoid deoxycorticosterone acetate suppress long QT phenotype . Knockdown glucocorticoid receptor , conversely , androgen receptor show flurandrenolide act glucocorticoid receptor shorten ventricular action potential . The mechanism distinct traffic rescue defective zebrafish-ERG channel . The author discuss drug normalizing repolarization would novel therapeutic tool long QT syndrome conclude glucocorticoid could expect aid acute management patient long QT syndrome , e.g . episode arrhythmic storm . In addition , corticoid induced normalization QT interval report patient drug-induced prolongation QTc interval . Brostoff et al . report patient suffer mucocutaneous leishmaniasis treat sodium stibogluconate . During therapy , QTc interval prolong return normal within 4 day start glucocorticoid therapy prednisolone 20 mg twice daily . Interrogation study : - shorten cortisone QTc-interval ? - long interval shorten QTc-interval ? - effect prolong ? - effect dose dependend ?</brief_summary>
	<brief_title>Cortisone QTc-Interval</brief_title>
	<detailed_description />
	<mesh_term>Cortisone acetate</mesh_term>
	<mesh_term>Cortisone</mesh_term>
	<criteria>patient underwent therapy cortisone ( &gt; =40mg/d ) patient elevate intracranial pressure myocardial infarction within last 6 month untreated stenosis coronary artery right bundle branch block autoimmune disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>